Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aceclidine - Lenz Therapeutics

Next Previous
Drug Profile

Aceclidine - Lenz Therapeutics

Alternative Names: LNZ-100; VIZZ

Latest Information Update: 08 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LENZ Therapeutics
  • Developer Corxel Pharmaceuticals; LENZ Therapeutics; Lotus Pharmaceuticals
  • Class Antiglaucomas; Azabicyclo compounds; Eye disorder therapies; Small molecules
  • Mechanism of Action Cholinergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Presbyopia

Highest Development Phases

  • Marketed Presbyopia

Most Recent Events

  • 05 Jan 2026 LENZ Therapeutics and Lunatu enters a licensing agreement to commercialize Aceclidine in United Arab Emirates, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon and Iraq
  • 02 Dec 2025 Preregistration for Presbyopia in South Korea (Ophthalmic)
  • 30 Sep 2025 Aceclidine - Lenz Therapeutics is available for licensing in World as of 30 Sep 2025. www.lenztx.com

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top